Antibody–Oligonucleotide-Drug Conjugate (AODC) Services
OligoLinker: Next-Generation Hydrophilic, Multi-Site, and Modular AOC Linkers
Overview
Antibody–Drug Conjugates (ADC) & AOC Evolution
Antibody–Drug Conjugates (ADCs) are powerful therapeutic modalities that combine the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. Traditional ADCs rely on direct chemical linkers, often facing challenges such as:
- Limited drug-to-antibody ratio (DAR)
- Payload hydrophobicity causing aggregation and immunotoxicity
- Lack of flexibility in conjugation site selection
- Reduced antibody stability during chemical modification
To address these limitations, Antibody–Oligonucleotide Conjugates (AOCs) have emerged as a versatile evolution. Oligonucleotides serve as hydrophilic, modular linkers capable of carrying multiple payloads with programmable precision. They also open new possibilities in imaging, intracellular delivery, and multi-functional ADCs.
Our Platform:
DNA Linker-Based ADC Technology
At YD Biolabs, we have pioneered a proprietary Antibody-Oligonucleotide Conjugate (AOC) platform that harnesses enzymatic DNA modification for site-specific, stable, and modular conjugation. This innovative technology provides precise control over payload attachment, enhances biocompatibility, and accelerates development timelines to meet your therapeutic and diagnostic needs.
Platform Advantages
Hydrophilic DNA Linkers
Minimize aggregation and reduce immunotoxicity commonly associated with hydrophobic payloads.
Multi-Site Conjugation
Enable attachment of diverse payloads, including small-molecule drugs, fluorophores, and oligonucleotides at multiple predefined sites.
Modular Nucleotide Design
Achieve rapid prototyping and customization through programmable DNA sequence control.
Antibody-Friendly Enzymatic Chemistry
Employ mild reaction conditions that preserve antibody structure and function throughout the conjugation process.
Our Services
Whether your aim is to improve ADC efficacy, achieve targeted intracellular delivery, or develop multi-functional antibody tools, YD Biolabs’ OligoLinker-based platform delivers unparalleled flexibility and precision.
Custom Linker Design
Oligonucleotide scaffolds enable flexible, tailored linker creation.
Site-specific conjugation
Precise antibody labeling with our proprietary DNA Linker technology.
DAR Optimization
Controlled and tunable drug-to-antibody ratios for improved efficacy and consistency.
Analytical Validation
Comprehensive testing for size, purity, aggregation, DAR, and function.
IP & Regulatory Support
Consultation and documentation for IP strategy and submissions.
Scalable Manufacturing
Process design compatible with commercial-scale production.
Workflow
Inquiry & Order
Provide project details (payload, target, application). We review your needs and propose a tailored strategy. Upon agreement, development begins.
Linker Sequence Engineering
Custom design of oligonucleotide linkers enables precise and modular attachment optimized for your payload.
Enzymatic Conjugation & Purification
Site-specific conjugation under mild conditions ensures antibody stability; purification removes byproducts yielding high-purity products.
QC & Characterization
Comprehensive testing (HPLC, electrophoresis, binding assays) confirms DAR, purity, aggregation profile, and functionality.
Delivery & Post-Delivery Support
Product is delivered with complete documentation and options for scale-up, assay support, or technical assistance as needed.
Case Studies:
Intracellular Delivery of Herceptin - OligoLinker - Fluorescent Molecules
We showcase the versatility of our AOC platform by conjugating fluorescent molecules to Herceptin via oligonucleotide linkers, enabling efficient antibody labeling and intracellular payload delivery without compromising the antibody’s binding ability.
Case 1: Herceptin–ssDNA Linker–Cy5 Conjugate
- Conjugate Design: Herceptin conjugated to single-stranded DNA labeled with Cy5
- Average DAR: 3.0 (measured by AEX-HPLC)
- Binding Activity: Equivalent to native Herceptin, as confirmed by binding assay
- Cellular Imaging:
- 0 hours: Fluorescence signal localized on the cell surface
- 3 hours: Clear internalization observed, with signal distributed inside the cells
This case demonstrates efficient intracellular delivery of the payload through AOC, without affecting the antibody’s binding ability.
Case 2: Herceptin–dsDNA Linker–Cy5/FAM Dual Label Conjugate
- Conjugate Design: Herceptin conjugated to double-stranded DNA, where one strand is labeled with Cy5 and the complementary strand is labeled with FAM.
- Average DAR: 1.3 (measured by AEX-HPLC)
- Binding Activity: Equivalent to native Herceptin, as confirmed by binding assay
- Cellular Imaging:
- 0 hours: Dual fluorescence signals are observed on the cell membrane.
- 3 hours: Fluorescence signals are internalized, confirming the cellular uptake of the dual-labeled AOC.
This dual-color system highlights the platform’s ability for multiplexed labeling and intracellular tracking.
